Cardiovascular Responses to Exercise in People Living With HIV/AIDS: Effects of Exercise Training

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age30-50
SponsorInstituto Nacional de Cardiologia de Laranjeiras

About this trial

Patients living with HIV (PLWHIV) have compromised muscle metaboreflex, which can cause exercise intolerance. This randomized controlled clinical trial will verify the effects of regular exercise on autonomic and hemodynamic responses to muscle ergoreflex activation in these patients. PLWHIV without regular physical exercise will be randomly assigned into an exercise training or a control group. The exercise training group will undergo regular physical exercise during 12 weeks (60-min session performed 3 times/wk with moderate intensity), while the control group will keep inactive. Another group consisted of inactive HIV-uninfected group will be included. The primary endpoints will be blood pressure and autonomic markers in response to the Stroop Color-Word Test and the activation of muscle ergoreflex, by means of the post-exercise circulatory arrest (PECA), which will be performed with and without the topical application of a capsaicin-based analgesic balm. Secondary endpoints will include heart rate, peripheral vascular resistance, stroke volume, cardiac output, blood lactate concentration, anthropometrics, and handgrip strength. The active and inactive PLWHIV groups will be evaluated before and after the exercise training, while the healthy group only at baseline.

Eligibility criteria

Qualifiers

diagnosis of HIv infection for at least 5 years;

use of combined antiretroviral therapy for at least 3 years;

asymptomatic and free from opportunistic diseases at enrollment.

Disqualifiers

regular physical exercise;

malnutrition;

presence of coronary artery disease, ischemic diseases, pulmonary disease, diabetes, Chagas disease, tuberculosis, heart failure, hypertension;

using pacemakers and/or antidepressant, antiarrhythmic or antihypertensive medication, especially beta-blockers.

Trial design

Treatments tested in this trial

  • Exercise training

Treatment groups

63 Participants
are divided into 3 treatment groups

Sponsors and collaborators

Instituto Nacional de Cardiologia de Laranjeiras

Lead sponsor

Rio de Janeiro State University

Sponsor institution

Rio de Janeiro State University

Collaborator